ECONOMIC-EVALUATION OF DRUGS AND ITS POTENTIAL USES IN POLICY-MAKING

被引:14
作者
JOHANNESSON, M
机构
[1] Centre for Health Economics, Stockholm School of Economics, Stockholm, S-113 83
关键词
D O I
10.2165/00019053-199508030-00003
中图分类号
F [经济];
学科分类号
02 ;
摘要
Interest in the economic evaluation of drug treatments is steadily increasing, but the impact of such evaluations on decisions concerning the use of drugs is unclear. In this article I examine different decision and policy situations where economic evaluations of drug treatments could potentially be used. Economic evaluations may be used as an aid to the development of treatment guidelines, decisions within healthcare organisations, and decisions relating to approval, reimbursement and pricing. Economic evaluations appear to be most useful in the development of treatment guidelines and as an aid to reimbursement decisions. The incentive to use economic evaluations embodied in the healthcare system is also important. It is argued that it is too early to introduce regulations that require the use of economic evaluations in, for example, reimbursement decisions. A more cautious approach might be preferred, where economic evaluations are used more selectively until the methodology and the field have developed further.
引用
收藏
页码:190 / 198
页数:9
相关论文
共 11 条
[1]  
Drummond M.F., Stoddart G.L., Torrance G.W., Methods for the economic evaluation of health care programmes, (1987)
[2]  
Weinstein M.C., Zeckhauser R., Critical ratios and efficient allocation, J Public Econ, 2, (1973)
[3]  
Mishan E.J., Cost-benefit analysis, (1976)
[4]  
Baumol W.J., Economic theory and operations analysis, (1972)
[5]  
Johannesson M., The Australian guidelines for subsidisation of pharmaceuticals: the road to cost-effcctive drug prescribing?, PharmacoEconomics, 2, (1992)
[6]  
Manning W.G., Keeler E.B., Newhouse J.P., Et al., The costs of poor health habits, (1991)
[7]  
Henry D., Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals, PharmacoEconomics, 1, pp. 54-67, (1992)
[8]  
Aristides M., Mitchell A., Applying the Australian guidelines for the reimbursement of pharmaceuticals, PharmacoEconomics, 6, pp. 196-201, (1994)
[9]  
Detsky A.S., Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada, PharmacoEconomics, 3, (1993)
[10]  
Drummond M.F., Rutten F., Brenna A., Et al., Economic evaluation of pharmaceuticals: a European perspective, PharmacoEconomics, 4, (1993)